Associated Genetic Biomarkers
Synovial sarcoma, X breakpoint 2 (SSX2) is a gene that encodes a protein that functions as a transcriptional repressor. The protein also elicits humoral and cellular immune responses in cancer patients. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions and insertions, and in-frame deletions are observed in cancers such as hematopoietic and lymphoid cancers.
SSX2 status serves as an inclusion eligibility criteria in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials that contain SSX2 status as an inclusion criterion, 2 are phase 1 (2 open).
The most frequent alterations to serve as inclusion eligibility criteria are SS18-SSX2 Fusion and SSX2 Expression .
Significance of SSX2 in Diseases
Malignant Solid Tumor +
SSX2 is an inclusion criterion in 2 clinical trials for malignant solid tumor, of which 2 are open and 0 are closed. Of the trials that contain SSX2 status and malignant solid tumor as inclusion criteria, 2 are phase 1 (2 open) .
Synovial Sarcoma +
SSX2 is an inclusion criterion in 1 clinical trial for synovial sarcoma, of which 1 is open and 0 are closed. Of the trial that contains SSX2 status and synovial sarcoma as inclusion criteria, 1 is phase 1 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.